Data from the INAVO120 trial support the approval of the inavolisib combination for those with PIK3CA-mutant breast cancer.
Approval Alert | Inavolisib/Palbociclib/Fulvestrant in PIK3CA+ Advanced Breast Cancer
Advertisement
Advertisement
Trending on CancerNetwork
1
BCMA CAR T-Cell Therapy Improves OS Vs Teclistamab in Multiple Myeloma
2
FDA Grants Priority Review to Giredestrant in ER+/HER2– Early Breast Cancer
3
GLP-1 Receptor Agonists Show Modest Reduction in HR+ Breast Cancer Incidence
4
Decoding RAMPART: Durvalumab Monotherapy Vs Combination Therapy in RCC
5